Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

136.18 -1.19 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Five Best And Worst Performing Healthcare Stocks In January 2023 ↗
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
News headline image
Neurocrine Biosciences Earnings Preview ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
 
Via Benzinga
News headline image
Why Voyager Therapeutics Stock Is Sinking This Week ↗
Investors are taking profits on this red-hot stock this week. 
Via The Motley Fool
News headline image
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
News headline image
7 A-Rated Stocks to Buy for Less Than $25 ↗
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market. 
Via InvestorPlace
News headline image
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
News headline image
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal ↗
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today. 
Via InvestorPlace
News headline image
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies ↗
 
Via Benzinga
News headline image
Have A Look At William Blair's Top Biotech Picks For 2023 ↗
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
News headline image
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally ↗
UnitedHealth is among medical stocks holding key support. 
Via Investor's Business Daily
News headline image
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
News headline image
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
News headline image
Looking Into Neurocrine Biosciences's Return On Capital Employed ↗
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90... 
Via Benzinga
News headline image
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review ↗
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
News headline image
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat ↗
The company raised its guidance for Ingrezza sales in 2022. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences: Q3 Earnings Insights ↗
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2022 ↗
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
4 Analysts Have This to Say About Neurocrine Biosciences ↗
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022 ↗
Upgrades 
Via Benzinga
News headline image
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market ↗
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
News headline image
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms ↗
Devon Energy leads this weekend's watch list of stocks in a tough market. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.